[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Browse DPYSL3

Summary
SymbolDPYSL3
Namedihydropyrimidinase-like 3
Aliases DRP-3; ULIP; CRMP4; CRMP-4; LCRMP; ULIP-1; collapsin response mediator protein 4 long; unc-33-like phosphopr ......
Chromosomal Location5q32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cytoplasm Cell projection, growth cone Note=Colocalizes with synaptic vesicle protein 2 in the central region of the growth cone.
Domain PF01979 Amidohydrolase family
Function

Necessary for signaling by class 3 semaphorins and subsequent remodeling of the cytoskeleton. Plays a role in axon guidance, neuronal growth cone collapse and cell migration (By similarity).

> Gene Ontology
 
Biological Process GO:0007015 actin filament organization
GO:0010720 positive regulation of cell development
GO:0010721 negative regulation of cell development
GO:0010975 regulation of neuron projection development
GO:0010976 positive regulation of neuron projection development
GO:0010977 negative regulation of neuron projection development
GO:0030031 cell projection assembly
GO:0030336 negative regulation of cell migration
GO:0031345 negative regulation of cell projection organization
GO:0031346 positive regulation of cell projection organization
GO:0040013 negative regulation of locomotion
GO:0044089 positive regulation of cellular component biogenesis
GO:0045665 negative regulation of neuron differentiation
GO:0045666 positive regulation of neuron differentiation
GO:0046847 filopodium assembly
GO:0048678 response to axon injury
GO:0050768 negative regulation of neurogenesis
GO:0050769 positive regulation of neurogenesis
GO:0051017 actin filament bundle assembly
GO:0051259 protein oligomerization
GO:0051260 protein homooligomerization
GO:0051271 negative regulation of cellular component movement
GO:0051489 regulation of filopodium assembly
GO:0051491 positive regulation of filopodium assembly
GO:0051764 actin crosslink formation
GO:0051961 negative regulation of nervous system development
GO:0051962 positive regulation of nervous system development
GO:0060491 regulation of cell projection assembly
GO:0061572 actin filament bundle organization
GO:2000146 negative regulation of cell motility
Molecular Function GO:0005539 glycosaminoglycan binding
GO:0016810 hydrolase activity, acting on carbon-nitrogen (but not peptide) bonds
GO:0017124 SH3 domain binding
GO:0031005 filamin binding
GO:0035374 chondroitin sulfate binding
GO:1901681 sulfur compound binding
Cellular Component GO:0005884 actin filament
GO:0015629 actin cytoskeleton
GO:0030027 lamellipodium
GO:0030133 transport vesicle
GO:0030426 growth cone
GO:0030427 site of polarized growth
GO:0031252 cell leading edge
GO:0031941 filamentous actin
GO:0044297 cell body
GO:0070382 exocytic vesicle
GO:0099503 secretory vesicle
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-422475: Axon guidance
R-HSA-399956: CRMPs in Sema3A signaling
R-HSA-1266738: Developmental Biology
R-HSA-373755: Semaphorin interactions
Summary
SymbolDPYSL3
Namedihydropyrimidinase-like 3
Aliases DRP-3; ULIP; CRMP4; CRMP-4; LCRMP; ULIP-1; collapsin response mediator protein 4 long; unc-33-like phosphopr ......
Chromosomal Location5q32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between DPYSL3 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolDPYSL3
Namedihydropyrimidinase-like 3
Aliases DRP-3; ULIP; CRMP4; CRMP-4; LCRMP; ULIP-1; collapsin response mediator protein 4 long; unc-33-like phosphopr ......
Chromosomal Location5q32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of DPYSL3 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolDPYSL3
Namedihydropyrimidinase-like 3
Aliases DRP-3; ULIP; CRMP4; CRMP-4; LCRMP; ULIP-1; collapsin response mediator protein 4 long; unc-33-like phosphopr ......
Chromosomal Location5q32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of DPYSL3 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-1.0230.0257
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-1.0940.577
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.9590.458
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.6240.292
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.3660.888
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.9510.771
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.3710.508
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.3650.84
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.3520.864
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.1710.911
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.0080.627
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.2780.2
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of DPYSL3 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 141705.9-5.91
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 41407.1-7.11
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277302.7-2.71
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275903.4-3.41
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.85.9-1.11
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)86016.7-16.70.429
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13117.707.71
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91606.2-6.21
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59011.1-11.11
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38275.37.4-2.11
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22139.109.10.519
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1614014.3-14.30.209
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolDPYSL3
Namedihydropyrimidinase-like 3
Aliases DRP-3; ULIP; CRMP4; CRMP-4; LCRMP; ULIP-1; collapsin response mediator protein 4 long; unc-33-like phosphopr ......
Chromosomal Location5q32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of DPYSL3. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolDPYSL3
Namedihydropyrimidinase-like 3
Aliases DRP-3; ULIP; CRMP4; CRMP-4; LCRMP; ULIP-1; collapsin response mediator protein 4 long; unc-33-like phosphopr ......
Chromosomal Location5q32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of DPYSL3. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by DPYSL3.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolDPYSL3
Namedihydropyrimidinase-like 3
Aliases DRP-3; ULIP; CRMP4; CRMP-4; LCRMP; ULIP-1; collapsin response mediator protein 4 long; unc-33-like phosphopr ......
Chromosomal Location5q32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of DPYSL3. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolDPYSL3
Namedihydropyrimidinase-like 3
Aliases DRP-3; ULIP; CRMP4; CRMP-4; LCRMP; ULIP-1; collapsin response mediator protein 4 long; unc-33-like phosphopr ......
Chromosomal Location5q32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of DPYSL3 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolDPYSL3
Namedihydropyrimidinase-like 3
Aliases DRP-3; ULIP; CRMP4; CRMP-4; LCRMP; ULIP-1; collapsin response mediator protein 4 long; unc-33-like phosphopr ......
Chromosomal Location5q32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between DPYSL3 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolDPYSL3
Namedihydropyrimidinase-like 3
Aliases DRP-3; ULIP; CRMP4; CRMP-4; LCRMP; ULIP-1; collapsin response mediator protein 4 long; unc-33-like phosphopr ......
Chromosomal Location5q32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting DPYSL3 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.